Adaptive deep brain stimulation: a new frontier in personalised care for people with Parkinson's disease

In early 2025, both the US Food and Drug Administration and the European Union granted approval for the use of adaptive deep brain stimulation systems in the treatment of Parkinson's disease. With its ability to monitor brain signals and adjust stimulation parameters accordingly, adaptive deep brain stimulation shows great potential, demonstrating comparable outcomes to conventional stimulation and offering a range of benefits, including personalised neuromodulation, greater treatment accessibility and improved quality of life for patients. Francesca Ramadan elaborates.